SynthesisBlood cancer journal2026
Subsequent CAR-T and engineered antibody for relapsed/refractory multiple myeloma following BCMA-targeted treatment: a systematic review and meta-analysis.
Yun Kang et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.